Winnow Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Winnow Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$784K	Sell	5,950 -312	-5%	-$41.4K	0.6%	61
2025 Q4	$889K	Sell	6,262 -548	-8%	-$79.4K	0.66%	59
2025 Q3	$960K	Buy	+6,810	New	+$923K	0.75%	55
2025 Q2	–	Sell	-6,697	Closed	-$741K	–	497
2025 Q1	$741K	Buy	6,697 +1,336	+25%	+$169K	0.68%	58
2024 Q4	$707K	Buy	+5,361	New	+$663K	0.7%	46

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Winnow Wealth's NBIX Position: Q1 2026 in Review

Winnow Wealth reduced its Neurocrine Biosciences (NBIX) stake by 5% in Q1 2026, selling an estimated $41.4K and leaving 5,950 shares worth $784K. The position accounts for 0.6% of the portfolio, ranked #61.

Winnow Wealth first reported a position in NBIX in Q4 2024 and has held it in 5 quarters since. The position peaked at $960K in Q3 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Winnow Wealth held 5,950 shares of Neurocrine Biosciences worth $784K as of Q1 2026.
Winnow Wealth sold 312 Neurocrine Biosciences shares in Q1 2026, an estimated $41.4K.
Neurocrine Biosciences made up 0.6% of Winnow Wealth's portfolio in Q1 2026, its #61 holding.
Winnow Wealth first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 5 quarters since.
Winnow Wealth's Neurocrine Biosciences position peaked at $960K in Q3 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Winnow Wealth's 13F filing for Q1 2026, filed 19 May 2026.